Navigation Links
Sanofi US and POZEN Sign Exclusive License Agreement for the Commercialization of PA8140/PA32540 Tablets in the U.S.
Date:9/4/2013

cal application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

POZEN Forward-Looking Statements Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on current market data and research (including third party and POZEN sponsored market studies and reports), management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to license our PA product candidates on terms and timing acceptable to us, our inability to file a new drug application with the FDA for our PA product candidates in the timeframe we anticipate, our failure to successfully commercialize our product candidates; costs and delays in the devel
'/>"/>

SOURCE Sanofi US
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Pasteurs Fluzone High-Dose Vaccine Significantly More Effective Than Standard Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older
2. Sanofi Pasteur Announces Shipment of First Lots of 2013-2014 Seasonal Influenza Vaccine in U.S.
3. Sanofi US and Joslin Diabetes Center Announce Results from Multicultural Outreach Pilot at American Diabetes Association Scientific Sessions
4. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
5. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
6. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
7. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
8. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
9. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
10. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
11. NextBio Announces Translational Medicine Partnership with Sanofi
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... PINE BROOK, N.J. , Sept. 22, 2014 ... developing antibody therapies to treat infectious disease, today ... adult volunteer safety studies of obiltoxaximab (ETI-204). Obiltoxaximab ... of inhalational anthrax and data from these studies ... when administered intravenously (IV) at the intended therapeutic ...
(Date:9/22/2014)...  AVT, Inc. (OTC Markets: AVTC) ( www.autoretail.com ), ... machines, announced today that they are starting production of ... unit is designed for placement inside optical shops and ... statistics, there are over 20,000 optical stores in ... world,s first automated kiosk dedicated to cleaning and sanitizing ...
(Date:9/22/2014)... , Sept. 22, 2014  Olympus, a ... solutions for medical and surgical procedures, among other ... deal with Munich -based Brainlab ... ® Navigation. This agreement applies to the ... cross-disciplinary U.S. sales and all distribution outside the ...
Breaking Medicine Technology:Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4
... Pevion Biotech AG today announced ... therapeutic Candida vaccine PEV7, demonstrating the generation of specific ... Furthermore, the results again confirm the capability of Pevion,s ... long-lasting immunity in humans against otherwise weak antigens ...
... Mass. and MIAMI, Jan. 16, 2012 Boston Scientific ... endpoint data from its ORION trial, demonstrating excellent outcomes ... patients with iliac artery disease, a form of peripheral ... insufficient blood flow.  Results were presented today by Daniel ...
Cached Medicine Technology:Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory in all Vaccinees 2Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory in all Vaccinees 3Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 2Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 3Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 4Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 5
(Date:9/22/2014)... Utah (PRWEB) September 23, 2014 ... and corporate training, will be attending and exhibiting ... the American Health Information Management Association (AHIMA) in ... September 27 through October 1, and Career Step ... on its suite of coding training products, including ...
(Date:9/22/2014)... (PRWEB) September 23, 2014 The Marietta ... helping to promote National Breast Cancer Awareness Month ... contribute awareness to cause, prevention, diagnosis, treatment and cure by ... offices across the U.S. , A pink edition Philips ... that can tell us why the Sonicare is important to ...
(Date:9/22/2014)... During the annual Oregon Health Care Association ... care and senior housing industry are recognized for their ... of others. , This year, Nicolette Merino, Regional ... awarded the OHCA Special Service Award. This award is ... assist OHCA in reaching strategic objectives or help achieve ...
(Date:9/22/2014)... York, NY (PRWEB) September 22, 2014 On ... Radio Network launched their first evening show, “KC After Dark.” ... Marcus Edwards, “KC After Dark” will air every Tuesday at ... a free iPad for the 50th caller, and because of ... well past the call in mark with 500 callers. ...
(Date:9/22/2014)... Sterling Heights, MI (PRWEB) September 22, 2014 ... will be partnering with Playworks, a local nonprofit that is ... At least 50 volunteers including UHY employees, their families and ... Americas School to help paint on cement games and graphics, ... , This outing was originally scheduled to occur in ...
Breaking Medicine News(10 mins):Health News:Career Step to Exhibit at AHIMA Convention September 27 through October 1 2Health News:Verde Pointe Dental Associates Participate in Breast Cancer Awareness Month 2014 with a Pink Philips Sonicare Giveaway 2Health News:Avamere Family of Companies Regional Director Nominated for the Oregon Health Care Association 2014 Special Service Award 2Health News:The Women’s Radio Network, WRNW1’s First Evening Show a Huge Success 2Health News:Local CPA Firm Gears Up To Revamp Detroit Elementary School Playground 2Health News:Local CPA Firm Gears Up To Revamp Detroit Elementary School Playground 3
... Neuroradiologist in the Mayo clinic said that after the treatment ... ,He says that the treatment is very effective when compared ... ,He also explains that vertebroplasty is a process in ... compression fractures are present. These compressions arise due to osteoporosis. ...
... worst AIDS affected countries in the world, with an infection ... all // those who were in need of it. The ... to 110,000 people. The country is badly in need of ... entire nation will be destroyed socially and economically. ...
... might be using "substandard poultry vaccine", which could be the ... flu //in that country. ,Dr Robert Webster, ... that this problem was not confined to mainland China alone. ... vaccines. I think there are substandard vaccines for influenza in ...
... woman in Gopinathpur village after she underwent a family planning ... panic and confusion in the Kendrapara district. // ... been operated (tubectomy) as a part of the health camp, ... husband, Sudarshan, Jayanti had complaints of severe abdominal pain after ...
... validated from Medicare data as Medicare covers more than 40 ... be known from these data // reports Professor Richard Platt, ... useful for knowing the true benefits of the drug and ... the data obtained from Medicare would be far better than ...
... molecular link between the type 2 diabetes onset and ... fat. // This is because of the disruption in ... according to a recent research. According to the researchers, ... glycosyltransferase (GnT-4a) disrupts insulin production. ,The experiments ...
Cached Medicine News:Health News:Improved cure and activity level seen among patients treated by Vertebroplasty. 2Health News:Botswana Continues Its Fight Against AIDS 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: